NeuroSense announces results of in vitro study of PrimeC in ALS

NeuroSense Therapeutics announced the results of a non-sponsored in vitro study of PrimeC in amyotrophic lateral sclerosis, or ALS, conducted by Justin Ichida, at the University of Southern California’s, or USC, Stem Cell Ichida Lab, part of the Eli and Edythe Broad CIRM Center for Regenerative Medicine and Stem Cell Research at USC. Ichida’s in vitro study used induced pluripotent stem cells, or iPSCs, that were derived from blood samples of people living with ALS. The survival rate of induced motor neurons when administered with PrimeC in comparison to each of PrimeC’s components, ciprofloxacin and celecoxib, alone was evaluated. PrimeC showed a significant beneficial effect relative to each of its components alone, demonstrating the synergistic effect of PrimeC and supporting the rationale of combining the two active components into NeuroSense’s proprietary formulation. PrimeC attenuated ALS related pathology, as depicted by the increased survival rate. The PrimeC treated iPSCs had increased neuronal survival compared to ALS control cells, rendering their survival rate to be similar to healthy controls. Shiran Zimri, VP R&D of NeuroSense will be presenting these results at the 22nd Annual Northeast Amyotrophic Lateral Sclerosis Meeting which takes place October4-6, in Clearwater, Florida. NeuroSense expects clinical topline results from PARADIGM, its Phase 2b study of PrimeC in the treatment of ALS in the Q4.